QUINCY, Mass., Feb. 1 /PRNewswire/ -- Ivrea Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company focused on developing and commercializing novel treatments for dermatologic conditions, announced today the formation of a new Medical Advisory Board, to be chaired by Seth Orlow, M.D., Ph.D., to counsel it in its drug development efforts. This world class advisory group will provide medical input to the company as it finalizes its clinical and regulatory strategy, thus improving the likelihood innovative treatments will be commercialized.
"Ivrea is fortunate to benefit from the guidance and insights provided by this distinguished group of advisors," commented Dan Lynch, CEO of Ivrea. "All of its members are experts in their respective fields within dermatology and will bring years of experience and perspective to the task of optimizing our development strategies for our products, beginning with our promising gel for the treatment of onychomycosis."
"I am excited to be able to assemble a stellar group of colleagues to assist Ivrea in developing therapies that address our patients' unmet needs. I look forward to working with Dan Lynch and his team to bring on additional MAB members in the near future," said Dr. Orlow.
Members of the new Medical Advisory Board are:
Seth Orlow, M.D., Ph.D., is a co-founder and board member of Ivrea Pharmaceuticals and serves as chairman of the company's Medical Advisory Board. He is chairman of Dermatology and a professor of Dermatology, Cell Biology, and Pediatrics at New York University School of Medicine. A venture partner with Easton Capital Partners, Dr. Orlow currently serves on the boards of Protez Pharmaceuticals and Transave, Inc. He was also a founder of the Anaderm Research Corporation, a privately held drug discovery company acquired by Pfizer. Dr. Orlow has more than 15 years of experience as a consultant to major pharmaceutical companies, biotechnology companies, OTC manufacturers, and private equity firms on early and late stage pre-clinical drug discovery, clinical development, market opportunities, in-licensing, out-licensing, and strategy. He holds an A.B. in Biochemical Sciences from Harvard College and an M.D., Ph.D. in Molecular Pharmacology from Albert Einstein College of Medicine. Dr. Orlow trained in dermatology at Yale.
Guy Webster, M.D., Ph.D., received his degrees from the University of Pennsylvania and completed residency training in dermatology at New York University. An internationally recognized expert in acne, cutaneous infectious and inflammatory diseases and in the clinical development of dermatologic therapies, Dr. Webster has over 100 publications. Until 2005, he was professor and vice chairman in the department of Dermatology of Jefferson Medical College in Philadelphia where he also directed the clinical trials unit in the evaluation of therapeutics in dermatology. Currently, he is a clinical professor of Dermatology at Jefferson.
Lawrence Eichenfield, M.D., is chief of Pediatric and Adolescent Dermatology at Rady Children's Hospital, San Diego, and professor of Pediatrics and Medicine (Dermatology), at the University of California, San Diego (UCSD) School of Medicine. He earned his medical degree from Mount Sinai School of Medicine, was a pediatric resident and chief resident at Children's Hospital of Philadelphia, and completed dermatology training at the Hospital of the University of Pennsylvania. He is board certified in pediatrics, dermatology and pediatric dermatology. Dr. Eichenfield's clinical interests include atopic dermatitis, acne, laser surgery, and procedural pain control. He has appeared in front of FDA advisory boards and has been a principal investigator in numerous trials of topical and systemic agents for conditions including atopic dermatitis, fungal infections, acne and many others. Dr. Eichenfield serves on the board of the American Academy of Dermatology. He is editor-in-chief of Pediatric Dermatology and has published more than 150 journal articles, chapters and abstracts, and books.
Ivrea is a specialty pharmaceutical company focused on clinical development and commercialization of novel prescription pharmaceuticals for the treatment of dermatologic conditions. The company currently has two programs in clinical trials that leverage our proprietary topical delivery technologies: IVR 101/102 which combines our proprietary gels with known fungicidal active ingredients, thus creating unique dermatological prescription products for the treatment of onychomycosis that offer the safety of topical application while simultaneously providing the efficacy associated with oral medications, and IVR 103 which utilizes our proprietary platform technology to reduce the level of irritation associated with all trans retinoic acid (also called tretinoin) while uniquely maintaining efficacy in treating acne. The company's investors include Atlas Venture, Easton Capital, and CHL Medical Partners. For additional information about Ivrea Pharmaceuticals, visit the company's website, http://www.ivreapharma.com.
Ivrea Pharmaceuticals, Inc.